Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
about
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adultsPopulation pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsImpact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaborationExplaining adherence success in sub-Saharan Africa: an ethnographic studyStavudine toxicity in adult longer-term ART patients in Blantyre, MalawiMonitoring HIV viral load in resource limited settings: still a matter of debate?The Global Health Impact Index: Promoting Global HealthPatient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability.Focusing on quality patient care in the new global subsidy for malaria medicines.Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assayHepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.Transmitted drug resistance in nonsubtype B HIV-1 infection.Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian childrenNevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.Highly active antiretroviral therapy and employment status in accra, ghana.Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in CambodiaHigh efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, CambodiaDriving a decade of change: HIV/AIDS, patents and access to medicines for all.Identification of new, emerging HIV-1 unique recombinant forms and drug resistant viruses circulating in CameroonRetention in an antiretroviral therapy programme during an era of decreasing drug cost in Limbe, Cameroon.Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.Antiretroviral drug resistance and routine therapy, Cameroon.Metabolic function and the prevalence of lipodystrophy in a population of HIV-infected African subjects receiving highly active antiretroviral therapyEffectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial.Impact of the roll out of comprehensive emergency obstetric care on institutional birth rate in rural Nepal.When Medicine Meets Engineering-Paradigm Shifts in Diagnostics and TherapeuticsMolecular characterization of human immunodeficiency virus type 1 (HIV-1) and HIV-2 in Yaounde, Cameroon: evidence of major drug resistance mutations in newly diagnosed patients infected with subtypes other than subtype B.Rationale and uses of a public HIV drug-resistance databaseHIV drug resistance surveillance for prioritizing treatment in resource-limited settings.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.The price of adherence: qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda.Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.Generic and branded drugs for the treatment of people living with HIV/AIDS.Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.Adverse effects of highly active antiretroviral therapy in developing countries.
P2860
Q24246038-C4E7ADC5-FE93-4AEF-BDD5-9805A9F956ABQ24602072-46C0141E-C0C7-4498-8A11-9505E70A21A2Q24792432-BE8EA8A1-AAAB-4A8D-9B57-ED89E1D5EC9AQ28474661-9E4E3211-2D7E-479C-8426-FDD82FB57F57Q28481581-D06DC251-9351-4B73-BF1D-CA08FF3A855FQ28485511-179405EF-8E9B-439F-B22B-AFC479544DA8Q28551476-47B4451C-C960-4820-9600-3F2DC103B22EQ30528513-9196FFF0-9180-45F0-BE4B-BCECC636AAB8Q33484725-03FAACE8-BCA0-4C7F-90E7-6949DD26533EQ33497943-AA72438B-2798-4A28-8B65-B3F67E1197BBQ33535469-0A315CC7-67F1-44B1-93D5-632987897C8EQ33567164-63FB0C2C-0613-4FFD-92D6-F2DB37F5E7DCQ33839338-1852EC3E-77AB-413E-9C7F-B2A69B21A500Q33850152-4C91D0DB-BE61-469A-A373-05DC32ED7163Q33907223-9200BB23-C073-40BB-A983-9A463D9EBD3BQ33988155-565957C0-D15F-4C86-8542-8728DAE34C22Q34643240-F5A139BB-5FD3-4346-9EDD-2524DA7FC9F3Q34730386-EF71FFC8-CD0C-4E1E-8848-953C8BCD4693Q34769839-41054B41-0FAC-4F34-9F36-AC0DC59DAF46Q34808796-1EFA4576-8EC7-42DB-ADAE-21ABFE657226Q35054197-244E0C9F-A24C-49E3-8BB0-2200DBD096D8Q35126444-E997D186-32B9-450D-9A68-E5009516099EQ35575721-E21183D9-3184-4CFA-9403-C80BB9B0FA96Q35817460-C482D50C-C80B-44FF-B354-CC5D8A411C3AQ35823452-5069F6D6-38DE-464B-B537-ACFDA66A4A1CQ35883654-4B8D6591-E844-40A6-A91D-072713547B97Q36087985-6B3E1FBC-3FB0-403D-8D29-549061162B6EQ36102516-4C7F8C52-CEE1-4604-AD7A-0981F60AE087Q36297262-91ED8AE7-3CEC-47E7-A710-25B3EF072D0DQ36335257-55233E6C-2AEF-487F-A02F-1AD46DC69B14Q36423642-C573561D-4CE7-47F4-B056-E41D09A0C650Q36572115-AF8917A2-1B39-40C1-96BC-E019C8976F20Q36631571-69CC58FB-6C63-4D1A-883C-B5B0B1B9D500Q36650954-A1906FC8-3F52-484B-8BEC-9DBEEA4F2725Q36662587-AD8E36DB-2314-427A-A659-84CA680E886CQ36682500-D6C00660-7410-4983-92C6-B4D85FEDBC04Q36696351-865CADFA-3AA9-44F5-965A-DBA9061293FEQ36747879-2445229E-286D-4528-978C-B98546A06500Q36785839-6CBE0722-2BE3-47D1-9F75-1EB19C34FB57Q36945761-73292AD0-1064-4715-9D55-CAD24573CF89
P2860
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Effectiveness and safety of a ...... open-label multicentre trial.
@en
Effectiveness and safety of a ...... open-label multicentre trial.
@nl
type
label
Effectiveness and safety of a ...... open-label multicentre trial.
@en
Effectiveness and safety of a ...... open-label multicentre trial.
@nl
prefLabel
Effectiveness and safety of a ...... open-label multicentre trial.
@en
Effectiveness and safety of a ...... open-label multicentre trial.
@nl
P2093
P50
P1433
P1476
Effectiveness and safety of a ...... open-label multicentre trial.
@en
P2093
Anke Bourgeois
Bernadette Lactuock
Christian Laurent
Isabelle Andrieux-Meyer
Léopold Zekeng
Michel Kazatchkine
Michèle Tardy
Nathalie Nkoué
Rose Mougnutou
Viviane Nzeusseu
P356
10.1016/S0140-6736(04)16586-0
P407
P50
P577
2004-07-01T00:00:00Z